Targeting NF-kappaB for colorectal cancer

Area of Science:

• Oncology
• Molecular Biology
• Cancer Signaling Pathways

Background:

• Colorectal cancer (CRC) remains a leading cause of cancer mortality.
• Current therapies like anti-VEGF/EGFR treatments face challenges due to acquired tolerance.
• The NF-kappaB signaling pathway is increasingly recognized for its role in colon cancer.

Purpose of the Study:

• To review the evidence linking NF-kappaB activation to colorectal cancer.
• To explore the potential of NF-kappaB as a therapeutic target for CRC.

Main Methods:

• Review of scientific literature on NF-kappaB signaling in carcinogenesis.
• Analysis of NF-kappaB's role in CRC development and treatment resistance.

Main Results:

• NF-kappaB activation is implicated in both colitis-associated and sporadic CRC.
• Activated NF-kappaB correlates with cancer hallmarks, angiogenesis, and chemotherapy resistance.
• Existing NF-kappaB inhibitors show therapeutic promise.

Conclusions:

• Constitutive NF-kappaB activation is common in CRC and promotes treatment resistance.
• Targeting NF-kappaB presents a potential strategy to overcome chemotherapy resistance in CRC.
• Further investigation of anti-NF-kappaB therapies is warranted for CRC treatment.